Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-7-27
pubmed:abstractText
Human gliomas are known to be immunosuppressive. Recent reports have suggested novel strategies to overcome this immunosuppression, including immunogene therapy. We examined expression of 10 immunologically important molecules by human gliomas in vitro, and we discuss the implications for immunogene therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0148-396X
pubmed:author
pubmed:issnType
Print
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1169-77; discussion 1177-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10807250-Adult, pubmed-meshheading:10807250-Aged, pubmed-meshheading:10807250-Antigens, CD, pubmed-meshheading:10807250-Antigens, CD86, pubmed-meshheading:10807250-Antigens, CD95, pubmed-meshheading:10807250-Brain Neoplasms, pubmed-meshheading:10807250-Cytokines, pubmed-meshheading:10807250-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10807250-Female, pubmed-meshheading:10807250-Flow Cytometry, pubmed-meshheading:10807250-Gene Expression Regulation, Neoplastic, pubmed-meshheading:10807250-Gene Therapy, pubmed-meshheading:10807250-Gene Transfer Techniques, pubmed-meshheading:10807250-Genes, MHC Class I, pubmed-meshheading:10807250-Genes, MHC Class II, pubmed-meshheading:10807250-Glioma, pubmed-meshheading:10807250-Humans, pubmed-meshheading:10807250-Immune Tolerance, pubmed-meshheading:10807250-Male, pubmed-meshheading:10807250-Membrane Glycoproteins, pubmed-meshheading:10807250-Middle Aged, pubmed-meshheading:10807250-Tumor Cells, Cultured
pubmed:year
2000
pubmed:articleTitle
Human glioma immunobiology in vitro: implications for immunogene therapy.
pubmed:affiliation
Department of Surgery, University of Alberta, Edmonton, Canada.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't